Occult hypoperfusion and mortality in patients with suspected infection
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To determine, in the early stages of suspected clinically significant infection, the independent relationship of the presenting venous lactate level to 28-day in-hospital mortality.
Prospective, observational cohort study.
Urban, university tertiary-care hospital.
One thousand two hundred and eighty seven adults admitted through the emergency department who had clinically suspected infection and a lactate measurement.
Measurements and results
Seventy-three [5.7% (95% CI 4.4–6.9%)] patients died in the hospital within 28 days. Lactate level was strongly associated with 28-day in-hospital mortality in univariate analysis (p < 0.0001). When stratified by blood pressure, lactate remained associated with mortality (p < 0.0001). Normotensive patients with a lactate level ≥ 4.0 mmol/l had a mortality rate of 15.0% (6.0–24%). Patients with either septic shock or lactate ≥ 4.0 mmol/l had a mortality rate of 28.3% (21.3–35.3%), which was significantly higher than those who had neither [mortality of 2.5% (1.6–3.4%), p < 0.0001]. In a model controlling for age, blood pressure, malignancy, platelet count, and blood urea nitrogen level, lactate remained strongly associated with mortality. Patients with a lactate level of 2.5–4.0 mmol/l had adjusted odds of death of 2.2 (1.1–4.2); those with lactate ≥ 4.0 mmol/l had 7.1 (3.6–13.9) times the odds of death. The model had good discrimination (AUC = 0.87) and was well calibrated.
In patients admitted with clinically suspected infection, the venous lactate level predicts 28-day in-hospital mortality independent of blood pressure and adds significant prognostic information to that provided by other clinical predictors.
- Occult hypoperfusion and mortality in patients with suspected infection
Intensive Care Medicine
Volume 33, Issue 11 , pp 1892-1899
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Lactic acid/lactate
- Risk assessment
- Industry Sectors
- Author Affiliations
- 1. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, KB-23, 330 Brookline Avenue, 02215, Boston, MA, USA
- 2. Department of Emergency Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
- 3. Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA